Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED BALANCE SHEETS

v3.5.0.2
CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Current assets    
Cash $ 20,154 $ 7,851
Total current assets 20,154 7,851
Total Assets 20,154 7,851
Current liabilities    
Accounts payable 753,840 622,129
Accrued interest payable 274,368 182,678
Notes payable - current - related parties 582,022 489,095
Notes payable - current, net 163,574 157,324
Derivative liability payable 86,394
Stock subscription payable 54,750 55,882
Related party payables 496,656 412,656
Other payables 242,827 242,612
Total current liabilities 2,654,431 2,162,376
Total Liabilities 2,654,431 2,162,376
Stockholders' Deficit    
Preferred stock
Common stock, $.00001 par value; 100,000,000 shares authorized; 67,751,068 and 60,251,068 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively 677 602
Additional paid in capital 14,408,926 14,353,628
Accumulated deficit (17,001,034) (16,468,956)
Total Transbiotec, Inc. stockholders' deficit (2,591,431) (2,114,726)
Noncontrolling interest (42,846) (39,799)
Total Stockholders' Deficit (2,634,277) (2,154,525)
Total Liabilities and Stockholders' Deficit 20,154 7,851
Series A Convertible Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock